Synonyms: AMG 102 | AMG102
Compound class:
Antibody
Comment: Rilotumumab is a monoclonal antibody directed against hepatocyte growth factor (HGF), developed as a treatment for solid tumours.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence BLAST search using the heavy and light chain variable regions of rilotumumab provides 100% matches to sequences covered by patent US8609090 [1], and to the antibody with designation 2.12.1. |
References |
1. Burgess TL, Coxon A, Green LL, Zhang K. (2013)
Specific binding agents to hepatocyte growth factor. Patent number: US8609090. Assignee: Amgen Inc., Amgen Fremont Inc.. Priority date: 18/07/2003. Publication date: 17/12/2013. |